261 related articles for article (PubMed ID: 2478681)
1. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
2. [The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life].
Jiang CY; Zhu BL; Zhang YJ
Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):118-21. PubMed ID: 7523052
[TBL] [Abstract][Full Text] [Related]
3. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.
Goeckeler WF; Edwards B; Volkert WA; Holmes RA; Simon J; Wilson D
J Nucl Med; 1987 Apr; 28(4):495-504. PubMed ID: 3572535
[TBL] [Abstract][Full Text] [Related]
4. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP.
Lattimer JC; Corwin LA; Stapleton J; Volkert WA; Ehrhardt GJ; Ketring AR; Anderson SK; Simon J; Goeckeler WF
J Nucl Med; 1990 Aug; 31(8):1316-25. PubMed ID: 2384798
[TBL] [Abstract][Full Text] [Related]
5. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
7. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
8. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP.
Logan KW; Volkert WA; Holmes RA
J Nucl Med; 1987 Apr; 28(4):505-9. PubMed ID: 3572536
[TBL] [Abstract][Full Text] [Related]
10. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
[TBL] [Abstract][Full Text] [Related]
11. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs.
Lattimer JC; Corwin LA; Stapleton J; Volkert WA; Ehrhardt GJ; Ketring AR; Hewett JE; Simon J; Goeckeler WF
J Nucl Med; 1990 May; 31(5):586-93. PubMed ID: 2341893
[TBL] [Abstract][Full Text] [Related]
12. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
Ketring AR
Int J Rad Appl Instrum B; 1987; 14(3):223-32. PubMed ID: 3117736
[TBL] [Abstract][Full Text] [Related]
13. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
16. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
18. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP.
Goeckeler WF; Stoneburner LK; Kasi LP; Fossella FV; Price DR; Fordyce WA
Nucl Med Biol; 1993 Jul; 20(5):657-61. PubMed ID: 8358352
[TBL] [Abstract][Full Text] [Related]
19. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
20. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
